Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors

Autor: Madeddu, C., Gramignano, G., Lai, E., Pinna, G., Tanca, L., Cherchi, M.C., Floris, C., Farci, D., Pretta, A., Scartozzi, M., Macciò, A.

Publikováno v: In ESMO Open October 2024 9(10)

Immunonutrition supplementation for resectable gastric cancer during standard neoadjuvant chemotherapy of FLOT. A proof-of-concept protocol: I-SUPPLY

Autor: V. Pusceddu, C. Donisi, A. Pretta, F. Loi, R. Badas, P. Ziranu, M. Puzzoni, E. Lai, S. Mariani, E. Palmas, M. Pozzari, E. Cimbro, A.P. D’Agata, S. Pinto, F. Coghe, S. Bergamini, D. Fanni, G. Faa, T. Yoshino, M. Scartozzi

Publikováno v: ESMO Gastrointestinal Oncology, Vol 3, Iss , Pp 100036- (2024)

The ‘immune pattern’ of the esophagogastric junction and gastric cancer (GC) has been related to tumour progression and/or response to therapies. GC can be classified as immunogenic or immune-resistant based on the infiltration of the tumour micr

Externí odkaz: https://doaj.org/article/2ab347a217804cdf9c5446add8a420b7

Artificial Intelligence Models for the Detection of Microsatellite Instability from Whole-Slide Imaging of Colorectal Cancer

Autor: Gavino Faa, Ferdinando Coghe, Andrea Pretta, Massimo Castagnola, Peter Van Eyken, Luca Saba, Mario Scartozzi, Matteo Fraschini

Publikováno v: Diagnostics, Vol 14, Iss 15, p 1605 (2024)

With the advent of whole-slide imaging (WSI), a technology that can digitally scan whole slides in high resolution, pathology is undergoing a digital revolution. Detecting microsatellite instability (MSI) in colorectal cancer is crucial for proper tr

Externí odkaz: https://doaj.org/article/038c3319707b4220b923f29bb14d9493

CD44: A New Prognostic Marker in Colorectal Cancer?

Autor: Ziranu, Pina¹ (AUTHOR) an.pretta@gmail.com, Pretta, Andrea¹ (AUTHOR) mariani.step@gmail.com, Aimola, Valentina² (AUTHOR) vale.aimola@gmail.com, Cau, Flaviana² (AUTHOR) flacau@tiscali.it, Mariani, Stefano¹ (AUTHOR) alessandrapiadagata@gmail.com, D'Agata, Alessandra Pia¹ (AUTHOR) claudiacodipietro96@gmail.com, Codipietro, Claudia¹ (AUTHOR) daiana.rizzo94@gmail.com, Rizzo, Daiana¹ (AUTHOR) veronicadellutri@outlook.it, Dell'Utri, Veronica¹ (AUTHOR) giorgia.sanna98@hotmail.it, Sanna, Giorgia¹ (AUTHOR) giusymo.17@gmail.com, Moledda, Giusy¹ (AUTHOR) cadoni.andrea@outlook.it, Cadoni, Andrea¹ (AUTHOR) ele.lai87@gmail.com, Lai, Eleonora¹ (AUTHOR) marcopuzzoni@gmail.com, Puzzoni, Marco¹ (AUTHOR) valeria.pusce@gmail.com, Pusceddu, Valeria¹ (AUTHOR) marioscartozzi@gmail.com, Castagnola, Massimo³ (AUTHOR) massimo.castagnola@icrm.cnr.it, Scartozzi, Mario¹ (AUTHOR), Faa, Gavino^4,5 (AUTHOR) gavinofaa@gmail.com

Publikováno v: Cancers. Apr2024, Vol. 16 Issue 8, p1569. 18p.

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma

Autor: Letizia Procaccio, Valeria Merz, Morena Fasano, Vanja Vaccaro, Elisa Giommoni, Andrea Pretta, Silvia Noventa, Maria Antonietta Satolli, Guido Giordano, Clizia Zichi, Carmine Pinto, Camilla Zecchetto, Giulia Barsotti, Ferdinando De Vita, Michele Milella, Lorenzo Antonuzzo, Mario Scartozzi, Alberto Zaniboni, Rosella Spadi, Simona Casalino, Francesca Bergamo, Chiara De Toni, Davide Melisi, Sara Lonardi

Publikováno v: Cancer Medicine, Vol 12, Iss 13, Pp 14337-14345 (2023)

Abstract Background The NAPOLI‐I trial showed better outcome of nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil/leucovorin (5‐FU/LV) compared to 5‐FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) prog

Externí odkaz: https://doaj.org/article/2ba909e629d843ce87c0d79ae0e1a3c6